Lupin Healthcare (UK) Limited, a subsidiary of global pharmaceutical company Lupin Limited, has acquired Renascience Pharma Limited, a UK-based pharmaceutical company specializing in four key specialty products. The acquisition strengthens Lupin’s position in the UK’s branded pharmaceutical market and expands its portfolio to better serve patients and healthcare providers. Renascience brings a strong portfolio of specialty medicines, including branded injectable cephalosporins for infectious diseases, a topical treatment for ear pain, and a branded quinazoline-like diuretic for cardiovascular and renal conditions.
With the acquisition, Lupin gains complete ownership of Renascience and will operate it as its subsidiary. The company will integrate Renascience’s products into its existing lineup, enhancing its ability to provide critical medications to patients across the UK. Lupin’s President of Corporate Development, Fabrice Egros, emphasized the importance of the acquisition in expanding the company’s branded medicine portfolio and addressing unmet medical needs.
Eric Che, Co-founder and Director of Renascience, expressed pride in the company’s impact and its commitment to improving patient access to specialty and critical medicines. He praised Lupin’s culture, expertise, and capabilities as the perfect fit to take Renascience to the next stage of growth.
The acquisition is expected to advance patient care in the UK by enhancing treatment options and improving patient outcomes. Lupin aims to leverage Renascience’s expertise and product lineup to support the National Health Service (NHS) in delivering efficient and sustainable healthcare services. Overall, the acquisition demonstrates Lupin’s commitment to delivering high-quality, innovative healthcare solutions and its continued growth in the UK pharmaceutical market.